Compugen Ltd.

Stocks

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 23:00:00 09/07/2026 +03			5-day change	1st Jan Change
2.470 ^USD	+2.49%		+8.33%	+61.44%

06-15	Compugen Ltd. - Special Call
06-11	Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701 At ESMO Gynaecological Cancers Congress 2026	CI

Transcript : Compugen Ltd. - Special Call

Published on 06/15/2026 at 06:35 pm +03 - Modified on 06/15/2026 at 08:06 pm +03

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Danya Ben-Hail (Analysts)

Hello, everyone. Welcome to Jones fireside chat with Dr. Eran Ophir, President and CEO of Compugen. I am Danya Ben Hail, an analyst at Jones Research.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Compugen Ltd.

06-15	Compugen Ltd. - Special Call
06-11	Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701 At ESMO Gynaecological Cancers Congress 2026	CI
05-19	Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-18	Compugen Files $400 Million Mixed Shelf	MT
05-18	Compugen Ltd., Q1 2026 Earnings Call, May 18, 2026
03-02	Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-02	Compugen Ltd., Q4 2025 Earnings Call, Mar 02, 2026
02-12	Compugen announces the appointment of Michele Holcomb, Ph.D., to its board of directors	RE
02-12	Compugen Ltd. Appoints Michele Holcomb to Its Board of Directors, Effective February 11, 2026	CI
01-07	HC Wainwright Initiates Compugen at Buy With $4 Price Target	MT
12-17	Compugen Monetizes Portion of Cancer Treatment Future Royalties to AstraZeneca for Up to $90 Million	MT
12-17	Compugen Ltd. Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million	CI
12-17	Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca for up to $90 million	RE
12-17	Compugen Ltd. and Medimmune Limited Enter into Amendment Number 4 to the License Agreement	CI
11-10	Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI